Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055105 · ClinicalTrials.gov registry record
Modulation of Molecular Fingerprinting in Pediatric Sepsis
A clinical trial of Systemic Inflammatory Response Syndrome, sponsored by Phoenix Children's Hospital.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT02055105 is a study of Systemic Inflammatory Response Syndrome that is actively recruiting participants, run by Phoenix Children's Hospital. The registered enrollment target is 50 participants, below the 588-participant average among 5 other Systemic Inflammatory Response Syndrome trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02055105, a study of Systemic Inflammatory Response Syndrome, is actively recruiting participants, sponsored by Phoenix Children's Hospital.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.
Conditions Studied
Interventions
- PROCEDURE miRNA in Sepsis
Study Locations (2)
Arizona
- Phoenix Children's Hospital - Phoenix
- Phoenix Children's Hospital - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-03 |
| Est. Completion | 2027-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055105
The ClinicalTrials.gov registry entry for NCT02055105 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 588-participant average among 5 other Systemic Inflammatory Response Syndrome trials with a reported enrollment target (91% lower). The listed sponsor is Phoenix Children's Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Inflammatory Response Syndrome appearing as the primary indexed condition, and to 1 intervention - of which miRNA in Sepsis is the first listed.
NCT02055105 reports 2 study locations spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02055105 about?
NCT02055105 is a clinical study titled "Modulation of Molecular Fingerprinting in Pediatric Sepsis". The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.
What is the current status of trial NCT02055105?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2014-03. Estimated completion is 2027-10.
What conditions does trial NCT02055105 study?
This clinical trial studies the following conditions: Systemic Inflammatory Response Syndrome.
What interventions are being tested in trial NCT02055105?
The interventions under investigation include: miRNA in Sepsis (PROCEDURE).
Who is sponsoring clinical trial NCT02055105?
This trial is sponsored by Phoenix Children's Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02055105 being conducted?
This trial has 2 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Inflammatory Response Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
RECRUITING
-
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
COMPLETED · Phase 2
-
Feeding the Critically Ill During Phases of Altered Redox Status
COMPLETED · NA
-
Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.